Alpine Immune Sciences (ALPN -3.0%) announces that the first patient has been successfully dosed in its NEON-1 Phase 1 study of ALPN‑202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in patients with advanced malignancies.
As the study continues, ALPN-202 is likely to support in establishing the clinical relevance of localized CD28 costimulation to checkpoint inhibition in cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.